The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
03/08/2012
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
W81XWH-12-ALSRP-TDA
Opportunity Category:
Discretionary
Posted Date:
Mar 08, 2012
Creation Date:
Mar 08, 2012
Original Closing Date for Applications:
Jul 24, 2012
Current Closing Date for Applications:
Jul 24, 2012
Archive Date:
Aug 23, 2012
Funding Instrument Type:
Cooperative Agreement
Grant
Category of Funding Activity:
Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards:
2
Estimated Total Program Funding:
$4,800,000
Award Ceiling:
Award Floor:
CFDA Number(s):
12.420
--
Military Medical Research and Development
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Agency Name
Dept. of the Army -- USAMRAA
Description
The Therapeutic Development Award supports the preclinical assessment of therapeutics for ALS. The proposed studies are expected to be empirical in nature and product-driven but may have a hypothesis-driven approach, provided the focus is on therapeutics. It is anticipated that the agents and/or data generated from these awards will lead to the advancement of new therapies for ALS.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
